-
Uncategorized6 months agoLilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for...
-
Uncategorized6 months agoFDA finds lack of evidence for dry eye disease drug approval
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an...
-
Uncategorized6 months agoTGA approves trial for first-in-human multiple myeloma therapy
Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma. The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum...
-
Uncategorized6 months agoMestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors...
-
Uncategorized6 months agoFDA grants Fast Track Designation to rare disease treatment
The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for the rare paediatric disease late-infantile neuronal ceroid lipofuscinosis (LINCL/CLN2 disease). ...
-
Uncategorized6 months agoGenomics initiative could boost AI-designed therapeutics
A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics. The Trillion Gene Atlas,...
-
Uncategorized6 months agoRadiopharmaceutical programme to develop therapeutic targets
Biotechnology company Aptamer Group has launched a radiopharmaceutical programme to develop new therapeutic targets. The programme, launched in collaboration with Radiopharmium, will look to develop three strategic...
-
Uncategorized6 months agoRead the latest issue of DDW
The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications...
-
Uncategorized1 year ago
From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future
From Microbes to Materials—ZymoChem's Vision for a Plastic-Free FutureZymoChem's Vision for a Plastic-Free Future
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
Deep dive: Psychedelics back on FDA’s doorstep
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
